Improving Arteriovenous Fistula Patency

Status Completed

Clinical Trial Summary

All vascular access guidelines recommend monitoring and surveillance protocols to prevent vascular access complications in hemodialysis units.

However, in the case of second generation screening techniques which determine access blood flow measurement (QA), there is a huge controversy about it´s efficiency.

Although multiple observational studies find a decrease in the thrombosis rate and an increased primary assisted patency survival related to the use of these techniques, a recently published meta-analysis find contradictory results in the randomized controlled trials, affirming that the measurement of QA is useless in grafts and questionable in native arteriovenous fistulae (AVF).

We have designed a multicenter, prospective, open label, controlled, randomized trial, to prove the usefulness of the QA measurement using two complementary second generation techniques, Doppler ultrasound and Transonic dilution method, compared to the classical monitoring and surveillance methods.

The primary endpoint will be a reduction in the thrombosis rate with an increased assisted primary patency survival, and a cost effectiveness economic analysis.

As secondary endpoints we will analyze the impact over non-assisted primary patency survival and secondary patency survival.

Clinical Trial Description

Definition:

Multicenter, prospective, open label, controlled, randomized trial, to prove the usefulness of the QA measurement using two complementary second generation techniques, Doppler ultrasound and Transonic dilution method, compared to the classical monitoring and surveillance methods.

For Patient Registries:

Clinical data repository (CDR) paper notebook will contain all baseline patient characteristics and the information related to vascular access. These data will be collected by the different investigators and reviewed and included in data base by the study´s monitor.

This information will be included in a centralized computer database (SPSS 15.0 computer system) and encoded in order to preserve patients´ confidentiality. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02111655
Study type	Interventional
Source	Hospital Infanta Sofia
Contact
Status	Completed
Phase	N/A
Start date	September 1, 2012
Completion date	September 29, 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03826043` - THrombo-Embolic Event in Onco-hematology	N/A
Recruiting	`NCT04398628` - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed	`NCT05426564` - Exploratory Assessment of the Quantra® System in Adult ECMO Patients
Not yet recruiting	`NCT05830916` - Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
Recruiting	`NCT02972385` - Pharmacogenomics of Warfarin in Hispanics and Latinos
Completed	`NCT02917213` - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed	`NCT02439190` - CV004-007 Thrombosis Chamber Study	Phase 1
Completed	`NCT02526628` - Thrombosis and Neurocognition in Klinefelter Syndrome
Completed	`NCT02341638` - Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects	Phase 1
Completed	`NCT01855516` - Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin	N/A
Unknown status	`NCT00983112` - Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery	Phase 4
Completed	`NCT00412464` - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis	Phase 1
Completed	`NCT00346424` - Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters	Phase 3
Completed	`NCT00479362` - Anticoagulant Therapy During Pacemaker Implantation	Phase 4
Terminated	`NCT00303420` - Alteplase for Blood Flow Restoration in Hemodialysis Catheters	Phase 4
Completed	`NCT00143715` - Oral Vitamin K for Warfarin Associated Coagulopathy	Phase 3
Completed	`NCT00039858` - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Phase 4
Completed	`NCT00007410` - Genetic Architecture of Plasma T-PA and PAI-1	N/A
Completed	`NCT00000538` - Dietary Effects on Lipoproteins and Thrombogenic Activity	Phase 3
Completed	`NCT00005436` - Lupus Cohort--Thrombotic Events and Coronary Artery Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Improving Arteriovenous Fistula Patency — METTRO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms